Published by Iain Gilbert on 26th August 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
URL: http://www.digitallook.com/dl/news/story/35309328/...